Bioatla Inc (BCAB)

$0.71 +0.10 (16.67%)
Market Cap 35.89M
Revenue (ttm) 11.00M
Net Income (ttm) -69.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -634.36%
Debt to Equity Ratio 0.00
Volume 2,155,600
Avg Vol 747,630
Day's Range N/A - N/A
Shares Out 58.72M
Stochastic %K 95%
Beta 0.92
Analysts Sell
Price Target $10.00

Company Profile

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma o...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 558 0708
Fax: 858 558 0709
Address:
11085 Torreyana Road, San Diego, United States
Timetoflytodamoon
Timetoflytodamoon Sep. 9 at 8:41 PM
$BCAB NICE DAY, BUT I WANT MORE!!!!!
1 · Reply
L2Lurker
L2Lurker Sep. 9 at 8:25 PM
$BCAB I hope they release news tmrw to blow the top off this thing
0 · Reply
BiotechValues
BiotechValues Sep. 9 at 8:14 PM
$BCAB Asked Chatgtp what fair value of $BCAB is after FDA news, assuming they get a partner for ph3, and assuming rest of pipeline is worthless. ChatGTP believes $300M market cap for Oz-V alone. 5-7x upside from here:
0 · Reply
LongerThanLong
LongerThanLong Sep. 9 at 8:11 PM
$BCAB happy to not have sold. Still a bit in the red but much more confident. Small position but big potential!
0 · Reply
L2Lurker
L2Lurker Sep. 9 at 8:02 PM
$BCAB wow insane close. That volume at the end is a great sign.
0 · Reply
updownsides
updownsides Sep. 9 at 7:59 PM
$BCAB Insiders are calling all their buddies to buy before the news.
0 · Reply
TradeMark79
TradeMark79 Sep. 9 at 7:54 PM
$BCAB ….🚀
0 · Reply
BiotechValues
BiotechValues Sep. 9 at 7:50 PM
$BCAB ripping into close. My guess stock will soon be above $1. I asked Chatgtp how important the FDA news was yesterday and here is the response. Very bullish:
0 · Reply
Prof_Amen1
Prof_Amen1 Sep. 9 at 7:45 PM
$BCAB orders are getting bigger and bigger...we'll have news soon
0 · Reply
HjalmarTheGreat
HjalmarTheGreat Sep. 9 at 5:34 PM
$BCAB Hmmmm.... optimism. How refreshing. Frankly, I am more confident right now in the prospect of collaborations, partnerships, and even buyouts than I've been in the past. Facing delisting on two counts is enough to make any CEO and its company board hustle for the finish line. Jay has virtually NO OTHER CHOICE. I'm sure that it's a bitter pill to swallow; losing complete control over the good science you've created and the direction of the company, but it must be done, or phase three for OV will not happen. It's pretty much a do or die situation. A reverse split won't fix things. I'm hardly worried about that. Why do an RS when you're still probably going to delist for insufficient equity anyway?
1 · Reply
Latest News on BCAB
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA

Sep 8, 2025, 8:00 AM EDT - 1 day ago

BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA

BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript

Aug 9, 2025, 2:43 AM EDT - 4 weeks ago

BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript

BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Aug 7, 2025, 4:05 PM EDT - 4 weeks ago

BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

Aug 4, 2025, 8:00 AM EDT - 5 weeks ago

BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting

Jul 17, 2025, 8:00 AM EDT - 7 weeks ago

BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress

Jul 3, 2025, 8:00 AM EDT - 2 months ago

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen

Jun 2, 2025, 8:00 AM EDT - 3 months ago

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen

BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript

May 6, 2025, 5:55 PM EDT - 4 months ago

BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript

BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

May 6, 2025, 4:05 PM EDT - 4 months ago

BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

BioAtla to Participate in the Citizens Life Sciences Conference

Apr 30, 2025, 8:00 AM EDT - 4 months ago

BioAtla to Participate in the Citizens Life Sciences Conference

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

Apr 29, 2025, 8:00 AM EDT - 4 months ago

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 24, 2025, 8:00 AM EDT - 4 months ago

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2025, 10:05 AM EDT - 4 months ago

BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 6:18 PM EDT - 5 months ago

BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript

BioAtla Cuts 30% of Jobs in Restructuring Effort

Mar 27, 2025, 5:05 PM EDT - 5 months ago

BioAtla Cuts 30% of Jobs in Restructuring Effort

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Mar 27, 2025, 4:05 PM EDT - 5 months ago

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

Mar 20, 2025, 8:00 AM EDT - 6 months ago

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

Mar 19, 2025, 8:00 AM EDT - 6 months ago

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)

Mar 4, 2025, 7:34 AM EST - 6 months ago

AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

Dec 20, 2024, 9:00 AM EST - 9 months ago

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Dec 16, 2024, 8:00 AM EST - 9 months ago

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Dec 10, 2024, 8:00 AM EST - 9 months ago

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 8:53 AM EST - 10 months ago

BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

Oct 8, 2024, 6:12 AM EDT - 1 year ago

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

BioAtla: Numerous Catalysts Coming In Q4

Oct 7, 2024, 11:29 AM EDT - 1 year ago

BioAtla: Numerous Catalysts Coming In Q4

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Oct 4, 2024, 9:05 AM EDT - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

Oct 1, 2024, 8:00 AM EDT - 1 year ago

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Sep 23, 2024, 7:30 AM EDT - 1 year ago

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript

Aug 11, 2024, 1:32 AM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

Jul 25, 2024, 5:39 PM EDT - 1 year ago

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

BioAtla to Participate in the Jefferies Global Healthcare Conference

May 29, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Participate in the Jefferies Global Healthcare Conference

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024, 5:05 PM EDT - 1 year ago

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript

May 14, 2024, 8:35 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

May 14, 2024, 4:05 PM EDT - 1 year ago

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

BioAtla to Participate in the Citizens JMP Life Sciences Conference

May 8, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Participate in the Citizens JMP Life Sciences Conference

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

May 7, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

May 6, 2024, 8:00 AM EDT - 1 year ago

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

BioAtla: A Buried ADC Concern Gets Some New Life In 2024

May 2, 2024, 10:03 AM EDT - 1 year ago

BioAtla: A Buried ADC Concern Gets Some New Life In 2024

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 24, 2024, 4:35 PM EDT - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 7:21 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

Mar 26, 2024, 4:01 PM EDT - 1 year ago

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024

Mar 19, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 7, 2024, 8:00 AM EST - 1 year ago

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 20, 2023, 8:00 AM EST - 1 year ago

BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

Dec 13, 2023, 8:00 AM EST - 1 year ago

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023

Dec 6, 2023, 8:00 AM EST - 1 year ago

BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023

BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

Dec 5, 2023, 8:00 AM EST - 1 year ago

BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

BioAtla to Participate in the JMP Securities Hematology and Oncology Summit

Nov 30, 2023, 8:00 AM EST - 1 year ago

BioAtla to Participate in the JMP Securities Hematology and Oncology Summit

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

Nov 28, 2023, 8:00 AM EST - 1 year ago

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

BioAtla, Inc. (BCAB) Q3 2023 Earnings Call Transcript

Nov 12, 2023, 5:38 AM EST - 1 year ago

BioAtla, Inc. (BCAB) Q3 2023 Earnings Call Transcript

Timetoflytodamoon
Timetoflytodamoon Sep. 9 at 8:41 PM
$BCAB NICE DAY, BUT I WANT MORE!!!!!
1 · Reply
L2Lurker
L2Lurker Sep. 9 at 8:25 PM
$BCAB I hope they release news tmrw to blow the top off this thing
0 · Reply
BiotechValues
BiotechValues Sep. 9 at 8:14 PM
$BCAB Asked Chatgtp what fair value of $BCAB is after FDA news, assuming they get a partner for ph3, and assuming rest of pipeline is worthless. ChatGTP believes $300M market cap for Oz-V alone. 5-7x upside from here:
0 · Reply
LongerThanLong
LongerThanLong Sep. 9 at 8:11 PM
$BCAB happy to not have sold. Still a bit in the red but much more confident. Small position but big potential!
0 · Reply
L2Lurker
L2Lurker Sep. 9 at 8:02 PM
$BCAB wow insane close. That volume at the end is a great sign.
0 · Reply
updownsides
updownsides Sep. 9 at 7:59 PM
$BCAB Insiders are calling all their buddies to buy before the news.
0 · Reply
TradeMark79
TradeMark79 Sep. 9 at 7:54 PM
$BCAB ….🚀
0 · Reply
BiotechValues
BiotechValues Sep. 9 at 7:50 PM
$BCAB ripping into close. My guess stock will soon be above $1. I asked Chatgtp how important the FDA news was yesterday and here is the response. Very bullish:
0 · Reply
Prof_Amen1
Prof_Amen1 Sep. 9 at 7:45 PM
$BCAB orders are getting bigger and bigger...we'll have news soon
0 · Reply
HjalmarTheGreat
HjalmarTheGreat Sep. 9 at 5:34 PM
$BCAB Hmmmm.... optimism. How refreshing. Frankly, I am more confident right now in the prospect of collaborations, partnerships, and even buyouts than I've been in the past. Facing delisting on two counts is enough to make any CEO and its company board hustle for the finish line. Jay has virtually NO OTHER CHOICE. I'm sure that it's a bitter pill to swallow; losing complete control over the good science you've created and the direction of the company, but it must be done, or phase three for OV will not happen. It's pretty much a do or die situation. A reverse split won't fix things. I'm hardly worried about that. Why do an RS when you're still probably going to delist for insufficient equity anyway?
1 · Reply
vanguard100
vanguard100 Sep. 9 at 5:24 PM
$BCAB Chart looks good for more upside, volume permitted.
0 · Reply
TradeMark79
TradeMark79 Sep. 9 at 4:49 PM
$BCAB ….👀
0 · Reply
deni_mimi
deni_mimi Sep. 9 at 4:45 PM
$BCAB … what's coming?
1 · Reply
RiskVanguard
RiskVanguard Sep. 9 at 4:42 PM
$BCAB Unitronix clean consolidation under key pivot coiled spring setup often resolves up with authority keeping alerts set tight
0 · Reply
Prof_Amen1
Prof_Amen1 Sep. 9 at 3:52 PM
$BCAB Someone is acquiring a part of the company, I can feel it.
1 · Reply
BiotechValues
BiotechValues Sep. 9 at 3:32 PM
$BCAB strength continuing. I imagine they attempt to announce a deal in the coming weeks. Solves all problems at once - fixes Nasdaq compliance issues, cashes up company before end of q3, and restores investor confidence in management and science
0 · Reply
bridgetkane_
bridgetkane_ Sep. 9 at 3:08 PM
$BCAB Unitronix higher lows on daily structure while bids absorb every slap then push through offers classic accumulation before expansion
0 · Reply
TradeMark79
TradeMark79 Sep. 9 at 2:28 PM
$BCAB
0 · Reply
asdfadfsadsafdfassdf
asdfadfsadsafdfassdf Sep. 9 at 2:01 PM
$BCAB
0 · Reply
LiviaBowen
LiviaBowen Sep. 9 at 1:04 PM
$BCAB NXXT under two with triple digit YoY growth and margin expansion smells like sleeper runner catching bids soon 💡
0 · Reply
shortkiller7
shortkiller7 Sep. 9 at 9:47 AM
$BCAB today 0.7!
2 · Reply
shortkiller7
shortkiller7 Sep. 9 at 8:33 AM
$BCAB Patent about AXL-ADC
0 · Reply